News & Videos - SALVARX GRP. ORD 2.5P

Portage Provides Additional Information Relating to the Independent Director Review of the Proposed Acquisition of SalvaRx Limited PR Newswire TORONTO, Dec. 19, 2018 TORONTO , Dec. 19, 2018 /PRNewswire/ - Portage Biotech Inc. (CSE:PBT.U) (OTC:PTGEF) (" Portage " or the " Corporation "). The purpose of this press release is to provide supplemental disclosure to the Corporation's management information circular and proxy statement dated November 26, 2018 (the " Circular ") in respect of the Annual...

Portage Shares to Resume Trading; SalvaRx Acquisition Meeting Materials Mailed and Filed on SEDAR PR Newswire TORONTO, Dec. 6, 2018 TORONTO , Dec. 6, 2018 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) – Further to its news release of November 27, 2018 , Portage Biotech Inc. ("Portage" or the "Company") is pleased to announce that its common shares will resume trading at the open on CSE tomorrow, December 7, 2018 with trading on OTC expected to resume shortly thereafter. The mailing of...

Portage announces setting of meeting date to approve SalvaRx acquisition PR Newswire TORONTO, Nov. 21, 2018 TORONTO , Nov. 21, 2018 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Further to its news releases of August 28 and October 9, 2018 , Portage Biotech Inc. ("Portage" or the "Company") is pleased to announce that it has set a shareholder's meeting date to approve the Company's proposed acquisition of SalvaRx Limited from SalvaRx Group plc. The meeting is scheduled for January 8 th ,...

Portage provides update on SalvaRx portfolio company, Intensity Therapeutics, Inc. PR Newswire TORONTO, Oct. 22, 2018 TORONTO , Oct. 22, 2018 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a SalvaRx Limited portfolio company, Intensity Therapeutics, Inc. ("Intensity"). SalvaRx Limited holds an 8.5% equity interest in Intensity. Intensity has announced that results from its clinical trial IT-01 were presented at...

Portage provides update on proposed acquisition of SalvaRx PR Newswire TORONTO, Oct. 9, 2018 TORONTO , Oct. 9, 2018 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Further to its news release of August 28, 2018 , Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update regarding its proposed acquisition of SalvaRx Limited from SalvaRx Group plc ("SalvaRx"): CSE is continuing to review Portage's filing and is working as expeditiously as possible. Portage will issue a...

Portage Provides update on proposed acquisition of SalvaRx PR Newswire TORONTO, Aug. 28, 2018 TORONTO , Aug. 28, 2018 /PRNewswire/ - (CSE: PBT.U) (OTC: PTGEF) Portage Biotech Inc. ("Portage" or the "Company") wishes to announce that, further to its news release of August 14, 2018 announcing the proposed acquisition of SalvaRx Limited from SalvaRx Group plc, it has now submitted draft shareholder meeting materials to CSE for review. Until the meeting materials have been approved by CSE for...

Portage to Acquire SalvaRx Limited PR Newswire TORONTO, Aug. 14, 2018 TORONTO , Aug. 14, 2018 /PRNewswire/ - (CSE: PBT.U) (OTC Markets: PTGEF) Portage Biotech Inc. ("Portage" or the "Company") wishes to announce that, subject to regulatory and shareholder consent, it has reached a definitive agreement to acquire 100% of SalvaRx Limited (the "Transaction"). The vendors are SalvaRx Group plc (SALV:LSE), (94.2%), James Mellon (2.9%) and Gregory Bailey (2.9%) (collectively, the "Vendors"). Under the...